A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512884-30-00

Acronym

FBCSG-01-2007

Enrollment

520

Registered

2024-04-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Brief summary

Invasive disease-free survival

Detailed description

Overall survival; Distant disease-free survival; Left ventricle ejection fractions; Adverse event rate; Quality of life

Interventions

DRUGPerjeta 420 mg concentrate for solution for infusion

DRUGPERTUZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Invasive disease-free survival	—

Secondary

Measure	Time frame
Overall survival; Distant disease-free survival; Left ventricle ejection fractions; Adverse event rate; Quality of life	—

Countries

Finland, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026